Salah-Eddin Al-Batran, MD, on Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer: Expert Point of View

November 10, 2026

Salah-Eddin Al-Batran, MD, of Frankfurt Institute of Clinical Cancer Research (IKF), provides commentary on the clinical implications of the findings of the CLARITY-Gastric 01 trial, which evaluated the CLDN18.2-targeting antibody-drug conjugate sonesitatug vedotin vs investigator’s choice of therapy after at least one prior therapy for gastroesophageal cancer expressing CLDN18.2 (Abstract LBA7). 

Related Content